• Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Cision Canada
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • Analytics
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • Analytics
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Quebec Star Sprinter & High Tech Knee Simulator Highlight Impact of Knee Pain


News provided by

SANOFI CANADA

06 Jun, 2013, 15:17 ET

Share this article

Share this article


Surin on Knee Pain and Synvisc-One®, A Therapy for Osteoarthritis of the Knee

MONTREAL, June 6, 2013 /CNW/ - Sanofi Canada and Olympic sprinter Bruny Surin are teaming up to spotlight the impact of knee pain with a unique public awareness education tool; a high tech simulator that mimics the pain and loss of mobility associated with osteoarthritis of the knee. The event took place today at Place Ville Marie in downtown Montreal, with an enthusiastic and engaged audience.

Experts estimate that three million Canadians suffer from osteoarthritisi.  Often people who suffer from osteoarthritis of the knee cope by taking over-the-counter or prescription pain pills - and, in Surin's case, may even be forced to avoid activities and hobbies they love.

"I've always trained hard and about three years ago, I developed very sharp pain in my left knee, which made it impossible for me to run.  Even walking was very painful and I could not believe how much the pain slowed me down," says Surin. "Until you experience the pain of osteoarthritis, you just don't understand how hard it is to cope with. Now that I know what it is and how to manage it, I have a plan that works and I want to help other people get off the sidelines this summer."

That's why Surin teamed up with Sanofi Canada to debut the Sanofi Synvisc-One® Simulator, a high tech, electronic device that simulates the pain and loss of mobility that people who live with osteoarthritis of the knee face every day.  The simulator was created by Canadian bio-tech firm Bionik Labs as a teaching and awareness tool.

Surin Seeks the Best Solutions to Manage His Health

Surin was diagnosed with osteoarthritis of the left knee by Dr. Pierre Ranger, Orthopedic Surgeon (knee specialist), Associate Professor at the University of Montreal and Medical Director at Centre de Médecine Sportive de Laval, who has been treating Surin for more than 20 years. He manages the pain with a combination of a healthy diet, low-impact exercise and twice annual Synvisc-One® injections to cushion and lubricate the knee joint providing pain relief over 6 months.

Surin said that before his diagnosis, he experienced so much pain that he was afraid that surgery might be his only option, but was relieved to learn that there were other less invasive treatments available.  "Dr. Ranger surprised me by suggesting an injection," recalls Surin who now gets two annual Synvisc-One® injections to manage pain and help protect his knee from further damage.  "I'm a healthy, active guy, so I like to manage my health in the simplest way possible.  Synvisc-One® really works for me and I can train and enjoy my life again."

While there's been much buzz about supplementation and steroids, Dr. Ranger says that not enough attention has been paid to visco-supplementation, such as Synvisc-One®, which is a non-invasive injectable for the knee that lubricates and cushions joints to relieve pain and improve mobility and range of motion.

"By the time we hit 35 or 40 years old, most of us will have some wear and tear in our knees, which can develop into osteoarthritis of the knee, a painful condition. It's important to find the right treatment for you, along a healthy diet and exercise, to help combat osteoarthritis," explains Dr. Ranger.

Visit the newly launched Synvisc-One® website at www.synviscone.ca to learn more about osteoarthritis of the knee, Synvisc-One® and to find a doctor near you.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs.  Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.  Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). Sanofi companies in Canada include Sanofi Canada (pharmaceuticals), Sanofi Pasteur (vaccines), Sanofi Consumer Health (health and beauty), Genzyme (rare diseases) and Merial (animal health).  Together they employ more than 1,700 people across the country.  In 2011, Sanofi companies invested $151.7 million in R&D in Canada, creating jobs, business and opportunity throughout the country.

About Synvisc-One®

Synvisc-One® (hylan G-F 20) is a visco-supplement injection for osteoarthritis of the kneeii.  Made from a substance that lubricates and cushions your joint, Synvisc-One® can provide knee pain relief and improved mobility over 6 months, with just one simple injectionii.  Synvisc-One® is only intended for intra-articular use by a physician to treat pain associated with osteoarthritis of the knee2.  Visit www.synviscone.ca to learn more, take an online knee pain assessment test and find a sports medicine clinic near you.

Synvisc®/Synvisc-One® (hylan G-F 20) is for intra-articular injection to treat pain associated with osteoarthritis of the knee. Synvisc®/Synvisc-One® contains small amounts of avian protein and should not be used in patients with related hypersensitivities. Adverse events involving the injected knee after intra-articular injections of Synvisc®/Synvisc-One® may include: transient pain and/or swelling and/or effusion. The post marketing experience has identified the following systemic events to occur rarely with Synvisc®/Synvisc-One® administration: rash, hives, itching, fever, nausea, headache, dizziness, chills, muscle cramps, paresthesia, peripheral oedema, malaise, respiratory difficulties, flushing and facial swelling. If venous or lymphatic stasis is present, Synvisc®/Synvisc-One® should not be injected into the knee. Synvisc®/Synvisc-One® should not be used in infected or inflamed knees or in patients having skin diseases or infections in the area of the injection site.

i The Arthritis Society. Osteoarthritis - Know Your Options. 11. Brochure accessed online at www.arthritis.ca [03/12/2013].

ii SYNVISC®/Synvisc-One® Product Monographs, Genzyme Canada Inc., July 18, 2008/March 2, 2009.

Image with caption: "Olympic sprinter Bruny Surin coaches Montrealers on maintaining good knee health at a public awareness event in Place Ville Marie today. (Photo courtesy: Synviscone.ca) (CNW Group/SANOFI CANADA)". Image available at: http://photos.newswire.ca/images/download/20130606_C5537_PHOTO_EN_27649.jpg

Image with caption: "Olympic sprinter Bruny Surin takes the Sanofi Synvisc-One Osteoarthritis Simulator for a spin. The high tech knee brace mimics the pain and loss of motion associated with osteoarthritis of the knee. (Photo courtesy: Synviscone.ca) (CNW Group/SANOFI CANADA)". Image available at: http://photos.newswire.ca/images/download/20130606_C5537_PHOTO_EN_27651.jpg

SOURCE: SANOFI CANADA

For further information:

For more information or to schedule an interview contact:
Anne Cayer or Samantha Ventresca at Strategic Objectives:
TEL (toll free): 1-866-366-7733 x283
E: [email protected]; [email protected]

Modal title

Organization Profile

Sanofi Canada

    Also from this source

  • DUPIXENT® (dupilumab injection) is now approved in Canada for the treatment of adult and adolescent patients (12+) with Eosinophilic Esophagitis

  • Libtayo® (cemiplimab) in Combination with Chemotherapy now approved in Canada for the First-line Treatment of Advanced Non-small Cell Lung Cancer

  • Health Canada approves BEYFORTUS™ (nirsevimab) for the prevention of RSV disease in infants

Contact Cision

  • 877-269-7890
    from 8 AM - 10 PM ET

  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2023 CNW Group Ltd. All Rights Reserved. A Cision company.